Comparison of efficacy in renoprotection between Azilsartan medoxomil and Enalapril : A randomized, open-labeled controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220426002

Enrollment

Registered

2022-04-26

Start date

2018-04-20

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, albuminuria hypertension, antihypertensive therapy, Azilsartan medoxomil, Enalapril microalbuminuria, macroalbuminuria, renoprotective effect

Interventions

In 24 weeks period, patients in the azilsartan group received a dosage of 40 -80 mg daily to control blood pressure less than 130/80 mmHg. All patients were scheduled for first followed-up visits at

Experimental Drug,Active Comparator Drug

Azilsartan medoxomil group,Enalapril group

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: hypertensive subjects age > 18 years old with albuminuria >30 mg/g Creatinine

Exclusion criteria

Exclusion criteria: 1.pregnancy or planned pregnancy 2. hyperkalemia (K > 5 meq/L) after medication treatment 3.serum creatinine increase > 50% after ACEi/ARB use 4.hypotension 5.intolerable side effects of ACEi 6.anaphylaxis , angioedema

Design outcomes

Primary

Measure	Time frame
urine albumin creatinine ratio 24 weeks mg/L, immunoturbid method	—

Secondary

Measure	Time frame
change in eGFR, safety outcomes 24 weeks ml/min/1.73 m2 (CKD-EPI),	—

Countries

Thailand

Contacts

Public ContactPloyrawee Thanaprirax

Phramongkutklao hospital and college of medicine

ployraweeth@gmail.com026444676

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026